Sheel Biotech IPO is a book-building issue open from September 30 to October 3, 2025, with a price band of ₹59 to ₹63 per share and aims to raise ₹34.02 crore. Sheel Biotech Limited operates in the biotechnology and floriculture sector, specializing in tissue culture plant propagation, organic farming, greenhouse construction, and landscaping services. With experienced promoters and focus on sustainable agriculture and biotech, Sheel Biotech IPO presents a promising opportunity for investors seeking exposure to the growing agritech and biotech sectors in India.
₹10
₹63
₹91.00
Expert Opinions
Market sentiment for Sheel Biotech IPO is cautiously optimistic, driven by steady revenue growth and profit expansion in a niche biotech and agriculture segment. Key company strengths include its diversified product portfolio in tissue culture, organic farming, and horticulture, backed by ISO certification and strong R&D capabilities. Risks relate to sector-specific challenges like dependency on seasonal and climatic factors, regulatory changes, and competitive pressures in biotech farming solutions.
The valuation analysis for financial year 2025 positions Sheel Biotech IPO with a Return on Equity (ROE) of 13.59%, Return on Capital Employed (ROCE) of 16.34%, and Net Asset Value (NAV) of ₹56.84, indicating sound returns and asset base management. For long-term investors, Sheel Biotech IPO offers exposure to India’s growing agritech and biotech industries, though variability in agricultural cycles requires prudent investment planning.
Investor Considerations
Sheel Biotech IPO has demonstrated steady company performance with revenue growth from ₹92.55 crore in FY 2024 to ₹102.27 crore in FY 2025 and a PAT margin of 10.45%, reflecting consistent profitability. The biotechnology and agritech sector outlook remains positive, supported by rising demand for sustainable agricultural solutions and government support for biotech innovation.
The Sheel Biotech IPO valuation for financial year 2025 shows a Price to Book Value of 1.11, EBITDA Margin of 14.71%, and Debt to Equity ratio of 0.21, indicating conservative valuation with low leverage. Growth prospects are supported by capacity expansion, R&D focus, and an increased product portfolio. Risks include regulatory changes, climate dependencies, and market competition. Long-term investors may benefit from growth potential in tissue culture and organic farming, while short-term investors should consider market liquidity and sector volatility.
| Date | GMP | Trend |
|---|---|---|
| 07 Oct 2025 13.15 | ₹10 | --- |
| 06 Oct 2025 11.44 | ₹10 | Up |
| 04 Oct 2025 11.25 | ₹8 | --- |
| 03 Oct 2025 19.27 | ₹8 | --- |
FAQs
The Grey Market Premium showed good accuracy in predicting Sheel Biotech IPO’s listing performance. With a final GMP of ₹10, it projected a premium of 15.9% over the issue price of ₹63. The stock listed at ₹91, delivering a 44.4% gain. This resulted in a large prediction error of 28.5%, where the GMP correctly signaled a positive listing but underestimated the actual gain, reflecting moderate reliability in this case.
Sheel Biotech IPO Current GMP is ₹10.
Sheel Biotech IPO Expected Returns is 15.87%.
Sheel Biotech IPO estimated listing price is ₹73.